



International Journal of Clinical Cardiology & Research

Editorial

Has Neglect of Haemodynamics led to the Wrong Pathway for Treatment of Arterial disease? -

Mark I.M. Noble*

University of Aberdeen, Foresterhill, Aberdeen AB25 2ZH, UK

***Address for Correspondence:** Mark I.M. Noble, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZH, UK, Tel: +016-748-40142; E-mail: mimnoble@abdn.ac.uk

Submitted: 22 May 2018; **Approved:** 16 July 2018; **Published:** 17 July 2018

Cite this article: Noble MIM. Has Neglect of Haemodynamics led to the Wrong Pathway for Treatment of Arterial disease? Int J Clin Cardiol Res. 2018;2(2): 050-052.

Copyright: © 2018 Noble MIM. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

The established treatment for arterial disease, such as coronary disease, is to establish the site of stenosis, to dilate the stenosis with angioplasty or surgery bypass, and to try to maintain the integrity of the arterial lumen with stents, mostly nowadays drug eluting stents, e.g., Percutaneous Coronary Intervention (PCI). The consequence is that a thrombogenic site remains, that has to be counteracted with dual anti-platelet therapy that carries bleeding complications with it. A recent study showed that heart stents for stable angina show no benefit over placebo [1,2]. It has also been shown that 12% of PCI patients are re-admitted within 30 days [3]. A study of 60 day re-admission after PCI showed that among 1193 enrolled patients, 71 (6.0%) underwent unplanned 60-day re-admission for unstable angina (35.3%), chest pain (21.1%), heart failure (14.1%), and acute myocardial infarction (11.3%); 40.8% patients underwent repeated PCI [4]. Drug eluting stents are associated with lower rates of restenosis but may be associated with later vascular complications, such as in-stent thrombosis, bleeding at vascular access sites, intracranially, and in the upper gastrointestinal tract [5]. This is all very unsatisfactory, so we should question whether we have taken a wrong pathway in the treatment of arterial disease. Perhaps we should take a look at old fashioned haemodynamics [6] to find a clue to a better pathway to tread?

ARTERIAL STENOSIS

At an arterial narrowing (stenosis),

$$\partial P = a_1 Q + a_2 Q^2$$

Where ∂P is the pressure drop across the stenosis, Q is the flow through the artery, a_1 and a_2 are proportionality parameters. This means that the relationship between the variables ∂P and Q is quadratic and stenotic resistance increases with flow. $a_1 Q$ expresses viscous resistance, while $a_2 Q^2$ expresses turbulence. Another quantitative expression of a stenosis is the area ratio A_s/A_o , where A_s is the cross-sectional area of the stenosis and A_o is the cross-sectional area of the open, normal artery; this can be expressed as a percentage as $(1 - A_s/A_o) \times 100$. As the same flow has to go through both the normal section, A_o and the much smaller A_s of the stenosis, the blood has to go faster, i.e., velocity of blood flow increases; this is called convective acceleration. One can easily observe this phenomenon by watching a placid full river running into a gorge.

Acceleration is determined by force according to Newton's second law of motion,

$$F = ma$$

Where, F is force, m is mass and a is acceleration. So, we envisage a mass of fluid accelerating into a narrowing of the artery exerting greater force, and just as objects in a river gorge feel force, so do blood cells in a stenosis. This effect is called shear stress, equal to the force divided by the area of the surface of the object.

Arterial Wall Stress

The effect of changes in wall stress on the arterial endothelium/glycocalyx complex has been described and discussed in a number of publications. In short, an increase in flow through an artery, due to an increase in downstream demand, causes the artery to dilate. This is commonly known as Flow Mediated Dilatation (FMD) [7] and is commonly used to assess arterial endothelial function. It has been suggested that this effect of increased shear stress at the arterial wall is

beneficial because the dilatation is mediated by nitric oxide [8], which is thought to be an anti-atherothrombosis factor by Louis Ignore (see his You-tube presentation), giving a scientific basis for the supposed beneficial effect of exercise [9].

Cells in Blood being Forced through a Stenosis

It is strange that no-one seems to have queried the mechanism of predilection of arterial thrombosis to occur in stenosis. Here the analogy of the river gorge does not hold. Whereas objects in the gorge are swept downstream, in an arterial stenosis there occurs a platelet rich thrombus growth. When developing an experimental model of coronary arterial thrombosis, we all experienced the fact that endothelial damage alone does not produce thrombosis. One has to apply a stenosis to set off thrombus growth [10-14]. Why has this fact been ignored? Why is current drug therapy based on the results of platelet aggregation only in response to endothelial damage? Is it not likely that there is something about the presence of arterial narrowing and the Haemodynamics of stenosis that is the correct target for therapy. It follows from the discussion of arterial stenosis above, that platelets within a stenosis are subjected to force and turbulence and that these factors activate them. The response of platelet activation is release of serotonin which is packed into their dense granules. Reduction of secretion of these dense granules is associated with marked protection from the development of arterial thrombosis, inflammation and neointimal hyperplasia after vascular injury [15]. The reason for this is that platelets are also activated by serotonin through the 5HT_{2A} receptor, so that serotonin released by stenosis haemodynamics activates more platelets which release more serotonin, setting up the well-known serotonin (in addition to other feedback mediators) positive feedback cycle [16]. The importance of serotonin in this platelet feedback process is its abolition by 5HT_{2A} receptors, for which at least 20 references are available, although in this context two may be enough! [13,14].

Detailed Imaging of Arterial Stenosis

With the modern imaging of internal organs using magnetic resonance, one can obtain much greater detail of the structure of stenosis, including complex ones at artery bifurcations together with the accompanying blood velocity patterns [17-19]. When this is combined with computational fluid dynamic measurements and multi-scale modelling [20-22] one perceives the exciting possibility that the force applied to each platelet might be calculated, leading to a prediction of which platelets are likely to be activated by the shear stress and release serotonin to trigger thrombus growth. Already, these techniques have been useful when applied to the study of atheromatous lesion growth and post stenting disease. Nevertheless, in practical cardiology today, it is predicted that the altered haemodynamics of stenosis, which have a variety of patho-anatomical features and abnormal blood flow patterns all activate platelets if the increase in shear stress and turbulence are sufficiently great.

Treatment of Arterial Stenosis-Induced Arterial Thrombosis based on Stenosis Haemodynamics

It follows immediately from the fact that stenosis thrombus growth is serotonin dependent, that treatment of arterial disease with 5HT_{2A} receptor antagonists is urgently required. The additional benefit of this approach is that, there being no serotonin in wounds, the prediction is that there will be no bleeding complications [17], as with dual antiplatelet therapy [5]. There is at least one of these drugs that has shown no change in bleeding time in patients [14,18].



Thus, the proposed treatment for the future is that patients with symptoms suggestive of arterial disease be prescribed a 5HT_{2A} antagonist. If the symptoms are acute, i.e., possible acute coronary syndrome, stroke, leg Ischaemia, the drug should be given intravenously. If not acute, the patient would be given a course of oral 5HT_{2A} antagonist. While the patient is thus protected, the patient undergoes investigation, e.g., angiography, MRI imaging [17-19], exploratory surgery, which will induce only normal operative bleeding. Any stenosis that is shown, resting, or upon stress testing, may then undergo an appropriate procedure to remove stenosis. Post intervention treatment will be chronic administration of a 5HT_{2A} antagonist with no fear of excessive bleeding, only normal bleeding.

REFERENCES

- Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *Lancet*. 2018; 391: 31-40. <https://goo.gl/KqXMnh>
- Jacqui W. Heart stents for stable angina show no benefit over placebo. *BMJ*. 2017; 359: j5076. <https://goo.gl/C8exCL>
- Tripathi A, Abbott JD, Fonarow GC, Khan AR, Barry NG, Ikram S, et al. Thirty-day re-admission rate and costs after percutaneous coronary intervention in the United States: a national readmission database analysis. *Circ Cardiovasc Interv*. 2017; 10: e005925. <https://goo.gl/GGJhwJ>
- Claudio M, Ilaria M, Fabrizio D'A, Pierluigi O, Umberto B, Giorgio Q, et al. Sixty-day readmission rate after percutaneous coronary intervention: predictors and impact on long-term outcomes. *Europ Heart J-Quality of Care and Clinical Outcomes*. 2015; 1: 79-84. <https://goo.gl/fQj52S>
- Bhala N, Taggar JS, Rajasekhar P, Banerjee A. Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment *BMJ*. 2011; 343: d4264. <https://goo.gl/zc954n>
- Westerhof N, Stergioulou N, Noble MI. *Snapshots of Hemodynamics*. 2nd Edition. Springer; Dordrecht. <https://goo.gl/FnMmTe>
- Markos F, Ruane O'Hora, T, Noble MI. What is the mechanism of flow mediated arterial dilatation. *Clin Exp Pharmacol Physiol*. 2013; 40: 489-494. <https://goo.gl/uq1wCz>
- Snow HM, Markos F, O'Regan D, Pollock K. Characteristics of arterial wall shear stress which causes endothelium-dependent vasodilatation in the anaesthetized dog. *J Physiol*. 2001; 531(Pt3): 843-848. <https://goo.gl/oV1yAQ>
- Napoli C, Ignarro SW, de Nigris F, Lerman LO, Rossi L, Guarino C, et al. Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice. *Proc Natl Acad Sci USA*. 2004; 101: 8797-8802. <https://goo.gl/YsKdXG>
- Folts JD, Rowe GG. Cyclical reductions in coronary blood flow in coronary arteries with fixed partial obstruction and their inhibition with aspirin. *Fed Proc*. 1974; 33: 413.
- Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. *Circulation*. 1976; 54: 365-370. <https://goo.gl/ng3u49>
- Folts JD. Experimental arterial platelet thrombosis, platelet inhibitors, and their possible clinical relevance. *Cardiovasc Rev Rep*. 1982; 3: 370-382.
- Torr S, Noble MI, Folts JD. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by the specific serotonin 5HT₂ receptor antagonist ritanserin. *Cardiovasc Res*. 1990; 24: 465-470. <https://goo.gl/wkhYhi>
- McAuliffe SJG, Snow HM, Cox B, Smith CTT, Noble MI. Interaction between the effect of 5-hydroxytryptamine and adrenaline on the growth of platelet thrombi in the coronary artery of the anaesthetised dog. *Brit J Pharmacol*. 1993; 109: 405-410. <https://goo.gl/fvuxMA>
- King SM, McNamee RA, Hough AK, Patel R, Brands M, Reed GL. Platelet dense granule secretion plays a critical role in thrombosis and subsequent vascular remodeling in atherosclerotic mice. *Circulation*. 2009; 120: 785-791. <https://goo.gl/V8292Q>
- Golebiewska EM, Poole AW. Platelet secretion: From hemostasis to wound healing and beyond. *Blood Rev*. 2015; 29: 153-162. <https://goo.gl/jJ8hN>
- Steinman DA. Image-based computational fluid dynamics modeling in realistic arterial geometries. *Ann Biomed Eng*. 2002; 30: 483-497. <https://goo.gl/3UEaPq>
- Long Q, Xu XY, Ariff B, Thom SA, Hughes AD, Stanton AV. Reconstruction of blood flow patterns in a human carotid bifurcation: A combined CFD and MRI study. *J Magn Reson Imaging*. 2000; 11: 299-311. <https://goo.gl/7VeBfB>
- Long Q, Xu XY, Nourne M, Griffith TM. Numerical study of blood flow in an anatomically realistic aorto-iliac bifurcation generated from MRI data. *Magn Reson Med*. 2000; 43: 565-576. <https://goo.gl/YbFGf2>
- Thorne BC, Bailey AM, Peircs SM. Combining experiments with multi-cell agent-based modeling to study biological tissue patterning. *Brief Bioinform*. 2007; 8: 245-257. <https://goo.gl/co4TgY>
- Sloot PMA, Hoekstra AG. Multi-scale modelling in computational biomedicine. *Briefings in Bioinformatics*. 2010; 11: 142-152. <https://goo.gl/cxSBxQ>
- Zhang Y, Barocas VH, Berceci SA, Clancy CE, Eckmann DM, Garbey M, et al. Multi-scale modeling of the cardiovascular system: disease development, progression, and clinical intervention. *Ann Biomed Eng*. 2016; 44: 2642-2660. <https://goo.gl/1Rzxfq>
- Noble MIM, Drake-Holland AJ. Preservation of hemostasis with anti-thrombotic serotonin antagonism. *J Hematol Clin Res*. 2017; 1: 019-025. <https://goo.gl/hgUuNQ>
- Noble MIM, Ford F, Cameron G, Drake-Holland AJ. The novel anti-thrombotic drug with no-bleeding excess. *J Cardiol & Cardiovasc Ther*. 2017; 6: 555684. <https://goo.gl/s95GCS>